Humanitarian Aid: Refugees in Greece and the Balkans

Jeremy Lefroy Excerpts

Tuesday 3rd November 2015 Commons Chamber

[Justine Greening]

The support we provide is very much driven by the needs set out to us by the agencies and non-governmental organisations with which we work. I can confirm to the hon. Gentleman that we have provided tents—for example, in Croatia—and we are playing our role in helping to make sure that when people arrive at reception centres, they are dealt with and processed properly.

As the right hon. Member for Normanton, Pontefract and Castleford (Yvette Cooper) set out, there is a real issue of scale, and Britain cannot solve that on its own. It is worth emphasising to the House that each of the countries where refugees are arriving is leading the response in that country, so it is up to UN agencies and NGOs to work as part of a national response by each country. As I have set out, Britain is also supporting those countries in order to have an adequate response. As the House has heard, there are real challenges, given the scale of the numbers and the flow of refugees who are arriving on European shores.

The hon. Gentleman talked about the UK taking its fair proportion. The reality is that we can be proud of the work the UK is doing to support refugees affected by the Syrian crisis—whether it is the work we are doing in the Mediterranean to save lives, the thousands of people who have been given asylum already, the approach we now have of relocating people from the camps safely and securely, or the kind of support closer to home that I have set out today. No country in Europe is doing more than the UK, and the House should be proud of that.

[Jeremy Lefroy (Stafford) (Con)]

May I thank the right hon. Member for Normanton, Pontefract and Castleford (Yvette Cooper) for asking this urgent question? I entirely agree with the points she made. May I also thank my right hon. Friend the Secretary of State for all the work that she and my hon. Friend the Under-Secretary of State for Refugees are doing? May I, however, urge the Government to engage directly with the Governments of countries which now have refugees? As winter comes, we cannot allow bureaucracy or any other impediment to get in the way of making direct contact to offer our support to the Governments of Greece and the other Balkan countries to ensure that no lives are lost needlessly.

[Justine Greening]

I can assure my hon. Friend that we are doing just that. The problem he sets out is one we commonly face when we are trying to help any refugees, wherever they are. We only have to look at some of the challenges in Lebanon, where many of the refugees are in so-called informal tented settlements. That means that it has been far harder for us to put in place water and sanitation and to get education to the children in some of those camps than it otherwise would have been compared with the work in Jordan, which, broadly speaking, has been more Government-driven from the word go. We are now facing the issue closer to home on our own shores in Europe. I assure my hon. Friend that we are working with those Governments, while also urging our other European partners to step up to the plate, too.

Oral Answers to Questions

Jeremy Lefroy Excerpts

Wednesday 28th October 2015 Commons Chamber

[Justine Greening]

There are two aspects to tackling climate change. The first, of course, is mitigation, and many developed countries such as the UK have significant plans in place to transition to low carbon economies. The second is adaptation, which is the challenge for many developing countries. It is about how they can ensure that they not only adapt to climate change, which often hits them first, but grow sustainably and develop nevertheless.

[Jeremy Lefroy (Stafford) (Con)]

I congratulate the Department on the excellent work it has done with the Nepali Government over many years on the community forestry programme, which has seen forestation increase in Nepal. Are there lessons to learn from that programme for other areas in which the Department operates?

[Justine Greening]

Yes, I think that the key is to work with the grain of human nature and put in place programmes that allow livelihoods to be more successful and profitable, and that can go hand in hand with protecting and preserving the environment. The programme to which my hon. Friend refers is one of a number that the Department has put in place to ensure that reforestation happens.

Tropical Diseases

Jeremy Lefroy Excerpts

Tuesday 27th October 2015 Westminster Hall

[Jeremy Lefroy (Stafford) (Con)]

I beg to move,

That this House has considered the work of the UK in tackling malaria and neglected tropical diseases.

It is a pleasure to serve under your chairmanship, Mr Davies. I refer Members to my declarations in the Register of Members’ Financial Interests. One thing that is not there that I need to declare is that I have been invited to become a trustee of the Liverpool School of Tropical Medicine. That has not yet been ratified, so will not be in the register.

I have secured this debate at a critical time in tackling malaria and neglected tropical diseases, which affect up to 1.4 billion people across the world. Just to explain, neglected tropical diseases include leprosy, lymphatic filariasis, schistosomiasis, soil-transmitted helminths—or worms—leishmaniasis, human African trypanosomiasis and Chagas disease. All those diseases are preventable and treatable using existing treatments, yet they continue to cause death and disability in a way that would simply not be acceptable were they endemic in the United Kingdom. This debate is particularly important as the 2015 Nobel prize in physiology or medicine was awarded this month for work on malaria and neglected tropical diseases. Professor Youyou Tu was awarded the prize for the discovery of artemisinin, which I will come on to later, and Doctor William C. Campbell of Ireland and the USA and Professor Satoshi Omura of Japan were awarded the prize for their discovery of avermectin, which is effective against river blindness, lymphatic filariasis and a growing number of other parasitic diseases.

Over the past decade and a half, the UK has taken a prominent role in the fight against malaria and neglected tropical diseases, and I will set out the great progress made and the challenges that face us if we are to see their elimination. I ask the Minister to consider the future of the UK’s programmes in both areas.

Twenty years ago, we were losing the fight against malaria—I declare an interest, having had it at least four times—and there was widespread resistance to the main drugs used to cure it: chloroquine and sulfadoxine-pyrimethamine. The international will to tackle malaria seemed absent. All of that changed with the adoption of the millennium development goals. MDG 6 targeted malaria, while MDG 4 focused on child mortality. We have to remember that children are the ones who suffer most from malaria, as more children die from malaria than adults. MDG 5 was on maternal health, and pregnant women are particularly at risk of catching and suffering from malaria. The fight against malaria has resulted in a 58% decline between 2000 and 2015 in deaths from malaria globally. The World Health Organisation estimates that that means that 6.2 million deaths from malaria have been averted, primarily among children under five in sub-Saharan Africa.

[Mr Gregory Campbell (East Londonderry) (DUP)]

I congratulate the hon. Gentleman on securing this debate. Does he agree that while significant progress has been made, the fact that 200 million new cases of malaria have been reported this year alone calls into question our legitimate and worthwhile attempt to try to eliminate malaria in the next 15 years?

[Jeremy Lefroy]

I entirely agree with the hon. Gentleman. Between 450,000 and 500,000 people—they are mainly children—are dying unnecessarily every year from the disease. How did the tremendous progress—I stress that huge progress has indeed been made—happen? Principally, reliable long-term funding enabled the development and implementation of various interventions, including prevention through insecticide-treated bed nets and the development of vaccines, and diagnosis through the rapid diagnostic tests that enable people, particularly children, to be diagnosed with malaria in the village, rather than having to come to a laboratory in a town when the malaria may be severe.

[Graham Stringer (Blackley and Broughton) (Lab)]

The hon. Gentleman makes a good point about the progress made and the different ways of making that progress. Does he agree that the earlier regression was partly to do with the mistaken banning of DDT in Africa and elsewhere?

[Jeremy Lefroy]

I agree with the hon. Gentleman. DDT was banned for clear, understandable reasons, but it had some severe consequences that resulted in malaria taking a grip in areas where it had almost been eliminated. Even today, when DDT is being used for indoor residual spraying, we are seeing its effectiveness when topically applied and carefully used.

There have been some tremendous advances in cures, notably in the artemisinin combination therapies, which I will come to and which are the subject, in part, of this year’s Nobel prize in physiology or medicine. There has also been the welcome development of new medicines. One of them is coming out of Dundee University, and I am sure other Members will wish to discuss that.

The UK has played a major role in providing the long-term funding. It was less than £100 million a year in 2000, but it now stands at £500 million. That is the direct result of the Chancellor’s pledge, while shadow Chancellor in 2007, to increase funding to tackle malaria to £500 million. It is not simply funding that is essential, however; we need the institutions through which the work can be done. It is pointless for several different nations to all work on their own programmes independently. Overseas development assistance is far too precious a commodity for that, so co-operation was essential from the beginning.

I remember how important the first artemisinin-based cures for malaria were when they came out in the mid- 1990s. At last, there was a cure that was very effective and had limited side effects, unlike chloroquine, which was increasingly ineffective, and Lariam, which was effective, but which, as I found out to my cost, had potentially severe side-effects. At between $10 and $15 a dose, the drug was unaffordable to almost all those who needed it. It needed to be more like $1 a dose at the most.

The Medicines for Malaria Venture was established in 1999 as a product development partnership, with considerable UK support from the Labour Government right from the beginning. Its aim was to take up promising new projects from pharmaceutical companies and help them to fruition, so that effective drugs would be available at a price affordable to the poorest and to developing countries’ health systems. The founders of MMV recognised that developing medicines for malaria was not commercially attractive to companies, as those who most needed the drugs were least able to pay prices that covered the costs of development. There is a big lesson there for our work on tackling antimicrobial resistance. Indeed, I believe that Professor Dame Sally Davies, the chief medical officer, refers to the example of MMV when talking in her book, “The Drugs Don’t Work”, about what we need to do to tackle antimicrobial resistance.

By bringing together Governments including Switzerland, the UK and the US, private foundations such as the Gates Foundation and the Wellcome Trust, pharmaceutical companies, critically including small companies and not just the majors, and researchers, MMV was able to do in co-operation what had not been possible in isolation. Two drugs that have come from that work are: Coartem Dispersible, which is for children and has had more than 250 million doses produced and distributed; and the artesunate injection, which is very effective against severe malaria—possibly more effective than quinine—and has had 35 million doses produced.

A second, larger example of co-operation was the Global Fund to Fight AIDS, Tuberculosis and Malaria, which was also established in the time of the Labour Government in 2002 to concentrate efforts to fight those diseases. The UK, along with the US, France and the Bill & Melinda Gates Foundation, was a prominent supporter of the fund right from its creation. Indeed, the first executive director was a Briton, Dr—now Sir—Richard Feachem. The fund has been responsible for supporting programmes in malaria-endemic countries, including programmes on the mass distribution of insecticide-treated bed nets and the introduction of rapid diagnostic tests.

A third example is the Malaria Vaccine Initiative of PATH, which supports the development of promising malaria vaccines. The most advanced is GlaxoSmithKline’s vaccine, which was developed in Belgium and is called RTS,S. It recently received approval from the European Medicines Agency and will, I hope, become available in the not too distant future.

The progress made in the past 15 years has in large part been down to political will through the millennium development goals and the work of the United Nations and the Governments of the United Kingdom, the United States and other countries increasing long-term funding, with the UK taking a lead alongside the US and the Bill & Melinda Gates Foundation.

[Mrs Helen Grant (Maidstone and The Weald) (Con)]

I congratulate my hon. Friend on securing this debate. Does he agree that the tenacity of malaria means that much more money will have to be spent to beat it? The Gates Foundation estimated that it could cost between $90 billion and $120 billion up to 2020 to deal with it. Does he agree that we must not take our foot off the pedal?

--- Later in debate ---

[Jeremy Lefroy]

My hon. Friend is exactly right, and we have seen the consequences of taking our foot off the pedal in the past. In Zanzibar, malaria was almost eliminated in the 1950s, but it came back with a vengeance. There was another programme in the 1980s, and the foot was taken off the pedal and it came back with a vengeance. The same has happened in Sudan and many other places, so we must deal with that. I think the figures she quoted are accurate, but if we manage to tackle malaria and get to virtual elimination, it will add more than $4 trillion dollars to world GDP, so it is a hugely important investment to make.

Improving health systems is another reason why we have seen progress in many developing countries, with increasing local funding, although some countries really need to step up to their pledges—for instance, the Abuja declaration of committing 15% of budgets to health, which only a few sub-Saharan countries do at the moment, along with unprecedented co-operation, which I have described. We will need all these and more as we face the challenge of the next 15 years, which is to meet the WHO’s global technical strategy for malaria 2016 to 2030.

On top of that, we face two forms of serious resistance: by the malaria parasite to artemisinin-based combination therapies in the Mekong region in south-east Asia, from where resistance to both chloroquine and sulfadoxine-pyrimethamine started and spread to sub-Saharan Africa, which is why it is vital to get on top of this; and by mosquitoes to the insecticides on bed nets, which are becoming resistant to pyrethroids. We also see serious outbreaks where bed net distribution has failed and health systems are weak. I believe my hon. Friend the Member for Mid Derbyshire (Pauline Latham) is going to describe one such instance later in this debate.

The UK is heavily involved in work to counter both those threats, through the Department for International Development’s work and the global fund supported by DFID in Myanmar, working alongside the Government there, and through the work of the Innovative Vector Control Consortium, based in the Liverpool school, in searching for and testing new insecticides for bed nets. The UK has therefore been at the forefront in so many different ways, whether through funding or research—from the London school, the Liverpool school, Dundee, York, Imperial, Keele and other universities, or from business, NGOs, or, above all, people. There are so many I would like to mention, but I will not because of time constraints, but the UK has fantastic scientists in this field at all levels.

Given the effectiveness of UK support for tackling malaria over the last 15 years, will the Minister undertake to do his utmost to maintain that for the future? I am asking the UK not to increase the level of funding, but to maintain current levels. Reaching £500 million a year is a great achievement and others need to come forward to support the UK in this, not least the countries in which malaria is endemic.

The WHO’s roll back malaria framework states that malaria interventions are very good value for money:

“Immunisation is the only public health intervention that has been shown to be more effective than malaria interventions. Beyond the financial return, investments in fighting malaria will have enormous positive effects on agriculture, education and women’s empowerment. They will also contribute significantly to reductions in poverty and the alleviation of inequality.”

Almost exactly the same can be said about the work on neglected tropical diseases. They affect 1.4 billion people—possibly an underestimate—bringing disability and sometimes death. They have a devastating economic impact, yet treating them is cheap and entirely possible. Co-operation plays a vital role, and host Governments have a vital role to play. Many of these diseases can be treated in parallel through local health systems. It makes sense to work together rather than in silos. We saw that when we visited the NTD control programme in Mkuranga district in Tanzania—I went with two other hon. Members in the all-party group on malaria and neglected tropical diseases—where they were tackling lymphatic filariasis, schistosomiasis, soil-transmitted helminth and trachoma all together. Universities also have a vital role to play. In the case of Mkuranga, an important partner was the schistosomiasis control initiative, based in the UK’s Imperial College London. Other universities are very important partners.

In the private sector, we have seen extraordinarily generous donations of drugs. I will list them because it is important that hon. Members understand the scale. Merck and Co. will donate Mectizan—ivermectin—for onchocerciasis and lymphatic filariasis in Africa for as long as it is needed, with no limit. GSK has already donated nearly 2 billion tablets of albendazole for lymphatic filariasis and will continue until elimination, and has also donated 1 billion per annum to de-worm school-aged children. Johnson & Johnson has donated 200 million tablets of mebendazole a year. Pfizer donated 70 million doses of azithromycin for trachoma in 2012 alone. Novartis has donated drugs for leprosy. Eisai, the Japanese company, has donated 2 billion tablets of Diethylcarbamazine for lymphatic filariasis, and E. Merck has donated 20 million doses of praziquantel a year, going up to 250 million tablets a year from 2016 for schistosomiasis. These are huge figures that will substantially reduce the costs of treatment in countries where those diseases are endemic.

There are also product development partnerships. As well as the Medicines for Malaria Venture and the Malaria Vaccine Initiative, we have the Drugs for Neglected Diseases initiative, which focuses on developing new treatments for the most neglected patients suffering from diseases such as human Africa trypanosomiasis, Chagas disease and lymphatic filariasis, as well as paediatric HIV. Again, the UK has taken a leading role. On top of the £50 million committed by the previous Labour Government, a further £195 million was pledged by the coalition. The UK is also the second largest funder of the Drugs for Neglected Diseases initiative, with £64 million donated, second to Gates, who has given $126 million. The one other donor with more than €20 million of donations is Médecins sans Frontières, which has donated €66 million.

The UK has also played a leading role by hosting the London conference—a big conference that set the path for the next few years; we need to find out where we have got to with that—and the declaration on neglected tropical diseases, an important declaration that I want to quote from:

“Inspired by the World Health Organization’s 2020 Roadmap on NTDs, we believe there is a tremendous opportunity to control or eliminate at least 10 of these devastating diseases by the end of the decade”—

that is just over four years away.

“But no one company, organization or government can do it alone. With the right commitment, coordination and collaboration, the public and private sectors will work together to enable the more than a billion people suffering from NTDs to lead healthier and more productive lives—helping the world's poorest build self-sufficiency.”

[Jim Shannon (Strangford) (DUP)]

I thank the hon. Gentleman for giving me a chance to speak in this debate. Obviously the issue is very important. The number of Members present is an indication of that. I have not yet heard—although I am sure he is coming to it—about the vast contributions that faith groups, churches and missionaries make throughout the world to eliminate poverty and help people to work their farms and so on. Almost every church in my constituency of Strangford has a project to give help directly to an area in Africa, the middle east and the far east. Does he recognise the good work that those churches and faith groups do?

[Jeremy Lefroy]

I do indeed. I am most grateful to the hon. Gentleman for that intervention. I recognise the huge amount of work done by faith groups and missions around the world. They often run remote hospitals, which even the state health system cannot afford to maintain. I have seen the work that they do. Indeed, my wife ran a public health education programme for 11 years in Tanzania and saw at first hand the work that was done when she worked for the Lutheran Church there.

I will not go through the London declaration in detail, because I want other hon. Members to speak, but I will quote the final words:

“We believe that, working together, we can meet our goals by 2020 and chart a new course toward health and sustainability among the world’s poorest communities to a stronger, healthier future.”

Real progress has been made in the past few years. To take one example of many highlighted by the Overseas Development Institute last year, Sierra Leone made great strides in preventing four of the five diseases that make up 90% of the world’s NTD burden: onchocerciasis, lymphatic filariasis, soil-transmitted helminth and schistosomiasis. In particular, on schistosomiasis, which can lead to death through liver disease and bladder cancer, 562,000 people in Sierra Leone received preventative treatment in 2009. By 2012, that figure had reached 1.4 million, which was 99% of those needing treatment. We have heard of the tragic trials of Sierra Leone in the past year and a half, but it is important that we also recognise the huge amount of work that Sierra Leoneans have done to treat many of these other diseases.

[Bob Stewart (Beckenham) (Con)]

When my hon. Friend refers to elimination, does he mean the elimination of a disease in human beings or the elimination of the scourge of these diseases from the face of the earth? Have I got that wrong, or is it a combination of the two?

[Jeremy Lefroy]

My hon. Friend is absolutely right to raise that distinction. The recent leader article on malaria in The Economist discussed eradication, which is what I believe we have to go for. There are slightly different meanings to elimination and eradication, but whatever it is, we have to aim for what we have seen with smallpox and are approaching with polio, with no one getting these diseases anymore.

[Bob Stewart]

I am sorry, but my question was really about the distinction between getting rid of a disease from the face of the earth, so that it is never there again and human beings cannot catch it, and dealing with a disease in a human being.

[Jeremy Lefroy]

Ultimately it is about making sure that human beings cannot catch a disease. Whether we can get rid of a disease from the face of the earth is another matter, because they have a tendency to come back. We have to ensure that we have the tools in place so that if a disease does return when we think it is eliminated, we can deal with it.

I have three questions for the Minister. What progress has been made in investing the additional £195 million committed by the coalition Government to work on neglected tropical diseases? Given the tremendous cost-effectiveness of interventions—we are talking about tackling diseases that affect 1.4 billion people by committing over four years the cost of running an average district general hospital in the UK for just one year—will the Minister look carefully at increasing the UK’s support for NTD work, especially drug discovery and support for programmes that strengthen health systems as they deliver prevention, diagnosis and cure? Finally, will he update us on the progress made on implementing the London declaration? We hosted the conference, so it is important that we take the lead in ensuring that the declaration comes to fruition.

Over the past 15 years great progress has been made on malaria and NTDs. The UK has been a vital part of that work, not just via funding from DFID, but through our scientists, universities, NGOs and voluntary organisations such as the Rotary Foundation, which has done tremendous work on malaria on top of its work on polio, and most certainly through our private pharmaceutical sector, whether in its commitment to research and development in unfashionable areas or in its direct donations of billions of doses of essential drugs. Nevertheless, the job is only half done for malaria, and even less so for NTDs. If the UK remains committed over the coming 15 years, I remain hopeful that we can make substantial progress. I ask the Minister to make that commitment. It is not about specific sums of money, but about an overall approach that recognises how much difference this work makes to billions of people and what an effective use of UK taxpayers’ money it is.

Let me conclude by quoting the leader article in The Economist from 10 October:

“Throughout history, humans and disease have waged a deadly and never-ending war. Today the casualties are chiefly the world’s poorest people. But victory against some of the worst killers is at last within grasp. Seize it.”

[Several hon. Members rose—]

Sustainable Development Goals

Jeremy Lefroy Excerpts

Thursday 10th September 2015 Commons Chamber

[Jeremy Lefroy (Stafford) (Con)]

I refer Members to my entries in the Register of Members’ Financial Interests. I commend the hon. Member for Glenrothes (Peter Grant) on an extremely thoughtful speech, and thank my hon. and learned Friend the Member for Sleaford and North Hykeham (Stephen Phillips) and the hon. Member for Liverpool, West Derby (Stephen Twigg) for their speeches and for proposing this debate. Indeed, I thank all Members who have spoken.

The millennium development goals have, by and large, been a success. Having lived in Tanzania throughout the 1990s, I saw what was happening in their absence. Malaria—I chair the all-party group on malaria and neglected tropical diseases—was taking a greater toll on people’s lives towards the end of the 1990s than at the beginning of that decade. The same can be said about many other diseases, but the introduction of the millennium development goals led to institutions such as the global fund and the Gates Foundation investing in tackling them. As a result, in the next few weeks we will hear about the tremendous progress made in cutting deaths from malaria by half, saving millions of lives over the past 15 years. Those lives would not have been saved but for the millennium development goals. Let us remember how much has been done through the MDGs.

The SDGs are of course far more ambitious, and I recognise that that raises some problems. The Sermon on the Mount is an incredibly ambitious statement. Every time I read it, I first realise how far I fall short, but at the same time it inspires me to go on to do better. It is the same with the SDGs. Every year, we should pick them up in debates such as this one. We will say, “Yes, we have made progress”, but they will also inspire us to do much better. I hope that the SDGs will do that in each member state that signs up to them. We must not lose ground against the millennium development goals or we will lose heart, as we will if the SDGs are simply not met and, for instance, we go backwards on infectious diseases.

I will mention four SDGs. On goal 3, on healthy lives, I want to echo the point made by the hon. Member for Glasgow North (Patrick Grady) about the need to take a long-term approach. I believe that we must look at incredible challenges, such as the challenge of anti-microbial resistance to drugs, which means that we need to look at the global goods in which we must invest in order to develop antibiotics. That is not a three or a five-year funding programme, but a 20-year funding programme.

When the Select Committee went to Nepal earlier this year, we saw the great results of DFID’s long-term work on afforestation. We must do more on that great long-term project. On goal 3, we must also do much more on the integration of healthcare systems, rather than having the silo mentality that there has been in the past, although it is starting to break down.

Goal 8, on sustained, inclusive and sustainable growth, is absolutely crucial. My hon. Friend the Member for Mid Derbyshire (Pauline Latham) has already mentioned it with specific reference to tourism. Hilton reckons that 70 million jobs may be created globally through tourism in the next 10 years. That will bring very good, high-value employment to countries that need it. We need full, productive employment and decent work for all.

Last night, I had a meeting with a great friend who works in Uganda and the Congo. Mainly as a result of his and his colleagues’ work, although with some support from DFID, he now works with 24,000 farmers in the Democratic Republic of the Congo, one of the poorest countries on earth. They have introduced a cocoa business that now brings tens of millions of dollars into the country and provides livelihoods for tens of thousands of people. That has been developed over the past few years, showing what can be done in the most incredibly difficult and challenging situations.

Goal 13 is on combating climate change and its impact. I had the privilege of walking with my daughter in the Swiss Alps a couple of weeks ago. I walked in the same mountains 35 years ago, when I worked in Switzerland. The glaciers are now less than half what they were then. That is on our doorstep in Switzerland; it is not Kilimanjaro, where I lived for 11 years and could see the glacier almost shrinking before my eyes. Climate change is a reality and, as the hon. Member for Glenrothes said, it is affecting countries such as Bangladesh right now.

Hon. Members have already referred to goal 16, on peaceful and inclusive societies. Without peace and inclusion and without greater equality within societies, we will not see development. I have just mentioned the Congo, and it is rare that there is development in the absence of peace; it takes much more effort.

I again want to mention Tanzania, where I had the pleasure to live. With the exception of the short war with Uganda, it has by and large been at peace since independence in 1961. Very few Tanzanians seek refuge elsewhere, because they want to stay in Tanzania, which is a peaceful and largely well-governed country. It is a poor country, but people want to stay there. Goal 16 is therefore absolutely crucial.

I again thank hon. Members for giving us the opportunity to discuss the SDGs today, but we must revisit them in detail every year so that we can be challenged and see where we have fallen short.

Oral Answers to Questions

Jeremy Lefroy Excerpts

Wednesday 8th July 2015 Commons Chamber

[Justine Greening]

In fact, the UK has in many respects pioneered how we ensure that children caught up in emergencies still get the chance to be in school. I pay tribute to the Norwegians for taking up the issue, too. We want more funding in this area. It is absolutely vital if we are to go beyond just providing life-saving supplies today to helping to preserve the futures of children for tomorrow.

[Jeremy Lefroy (Stafford) (Con)]

What is the Secretary of State doing to ensure that Lebanese schools educating both refugees and Lebanese children are supported at this very critical time?

[Justine Greening]

The main thing we are doing is to work hand-in-hand with the Lebanese Government, who have taken great steps over recent months to make sure that their schools can cope not only with their own children, but with a doubling in the number of Syrian refugee children who now need to use them. That means not just support for teachers, but support in schools, in their buildings and in textbooks as well.

Sub-Saharan Africa (Corruption and the Economy)

Jeremy Lefroy Excerpts

Wednesday 1st July 2015 Commons Chamber

[Grant Shapps]

Once again, my hon. and learned Friend is right to point out these problems, which indeed exist in many places in the world, and particularly in some of these markets. Last week, however, I was in a school in Zomba in Malawi announcing £11.6 million in DFID budget. In that case we have chosen to work with USAID, because it has an established programme. It has the contractors in place and we can be certain, as it is properly audited, that the money is being well spent. He is right to point out these issues and it is right that the Department works to clamp down on all these practices. Clearly, we must protect British taxpayers’ funds and we must, for the reasons he outlined, ensure that the worst-off people in the world—Malawi is in the world’s bottom five for income, with an average income of £179 a year—are not being subsidised, through corruption, by one of the wealthiest countries in the world, which we are fortunate enough to live in.

[Jeremy Lefroy (Stafford) (Con)]

Does the Minister agree that some of the most effective international development work is often done by small, local, community organisations? We may be talking about building schools, working in community health centres or other such things. One problem they find is accessing the funds that DFID or others provide. We often hear people say, “We would like to work with these people but we cannot do so because the grant size is too small.” Yet these organisations are probably the least corrupt and often the most effective.

[Grant Shapps]

My hon. Friend will be interested to hear that we were having that conversation in the Department only yesterday, and he is right to highlight it.

Let me turn to some of the things we are doing to combat these problems of corruption. First, we track and trace activities and funds. DFID works in and with developing countries to ensure that public bodies and public funds are serving the people. Over recent months, DFID country teams have been undertaking analyses of some of the constraints to growth, and the message is clear: corruption negatively influences investor confidence, as we have already established. To address that, we fund track and trace activities to shine a light on corruption and recover stolen assets. DFID has been supporting the extractives industry transparency initiative since 2002, working in 23 sub-Saharan African countries. DFID supports the International Centre for Asset Recovery, which provides practical legal assistance to countries trying to track, trace and recover funds; it has cases worth potentially $235 million in Kenya, $227 million in Tanzania, which I visited and where I discussed some of this just a few weeks ago, and $30 million in Malawi, which I was in last week. An awful lot of work is going on in track and trace.

We have also built capacity to stop behaviours and reduce the opportunities for corruption. We work with partners on the ground to build the capacity of civil society organisations and partner agencies. For example, in Nigeria, DFID has worked to reduce government funds being lost or stolen. That has resulted in some £1.5 billion of assets being recovered, and DFID is supporting 2,670 investigation cases. My hon. and learned Friend will rightly point out that that must have something to do with the scale of the problem, but none the less he will be pleased to know that UK-based police and intelligence units, and many other organs of the British state, are helping in the swift recovery of assets.

Thirdly, we are applying pressure to our international partners, and that is at the heart of this matter. We are working on that UN convention against corruption in partner countries and with the World Bank and the International Monetary Fund on strengthening financial action taskforces around the globe. We have been taking real leadership in these areas. DFID works with other G8 and G20 members, and through the UN, to strengthen the international architecture to combat corruption and illicit financial flows. I remind the House that the United Kingdom took the lead when we chaired the G8 in 2013, implementing a number of measures which have put the UK in a leadership position.

It is, however, important to continue raising our game and it goes without saying that we also take our responsibilities very seriously. All DFID offices must complete and regularly refresh anti-corruption and counter-fraud country strategies that highlight the critical barriers. I can provide my hon. and learned Friend with the assurance that as a result of this evening’s debate I will be taking even more interest in that matter over the coming weeks and months.

My hon. and learned Friend mentioned the ICAI report on DFID’s work in this area in 2014, when DFID’s resources on counter-fraud and anti-corruption were said to have been “fragmented”. We have taken a number of steps since then to address these things, but because of a lack of time I will not produce the entire list.

I want to touch on tax—the issue of tackling tax avoidance and tax evasion in developing countries—to which my hon. and learned Friend referred. As I mentioned, the UK led on the issue during its G8 presidency. What I did not mention was that more than 90 countries have now signed up to principles such as automatic tax information exchange and helping to tackle offshore tax evasion. We are working to champion the OECD’s base erosion and profit-shifting project. This is in relation to multinational companies moving profits in order not to pay tax where it should be paid.

A huge amount of work is going on across Whitehall. The Minister of State, Department for International Development, my right hon. Friend the Member for New Forest West (Mr Swayne), sits on a body that is responsible, across Whitehall, for trying to build the capacity to monitor these areas. The body has done a huge amount of work already in Britain to prevent corruption, and it is now turning its attention internationally.

Tackling global poverty is the right thing to do, and it is also in Britain’s interests. We will continue to insist that every Department and organisation that we fund adopts a zero-tolerance approach to corruption. We will also continue with our focus on tackling tax avoidance and tax evasion in the developing world. As I mentioned to the House a moment ago, as a product of this debate, my own attention will be more highly focused on the matter.

Question put and agreed to.

Oral Answers to Questions

Jeremy Lefroy Excerpts

Wednesday 3rd June 2015 Commons Chamber

[The Prime Minister]

I agree with the right hon. Gentleman that everyone who was party to those talks—they were exhaustive and lengthy talks, ending in an agreement—should implement that agreement in full. The agreement did include welfare reform. That is the first point and he is absolutely right. Whatever happens, we need to make sure that Northern Ireland and the Assembly have a sustainable and deliverable budget, so I hope that even at this late stage people will look at what they can do to make sure that happens.

[Jeremy Lefroy (Stafford) (Con)]

Q8. Last year saw record numbers of adoptions and prospective adopters, but there are still more than 3,000 children in care waiting to be adopted, with half of them having waited for more than 18 months. What plans does my right hon. Friend, who has a strong commitment on this issue, have to enable more children to be placed in a loving, stable family home sooner rather than later?

Oral Answers to Questions

Jeremy Lefroy Excerpts

Wednesday 18th March 2015 Commons Chamber

[Justine Greening]

Much of our work in the occupied Palestinian territories focuses on providing basic services, including education. At the Cairo conference one of the main concerns of donors was the need to end the perpetual cycle of violence, reconstruction, then destruction and violence and the need for more reconstruction. I agree with the hon. Lady that this cannot continue ad nauseam.

[Jeremy Lefroy (Stafford) (Con)]

T4. Last month my hon. Friend the Member for Congleton (Fiona Bruce) and I had the honour of meeting Eileen Lodge, who has committed 60 years of her life to working for the poor and sick in Nepal. Does my right hon. Friend agree that the work of her Department would be impossible without the dedication of hundreds of millions of people, of all nationalities, who serve in difficult and dangerous situations, often for little or no financial reward?

Ebola

Jeremy Lefroy Excerpts

Thursday 12th March 2015 Commons Chamber

[Justine Greening]

The hon. Lady asked, understandably, about the four other health care workers. They are now in the process of being flown home, purely on a precautionary basis, and will be dealt with at the Royal Free hospital and the Royal Victoria infirmary in Newcastle.

I had a chance to meet some of the orphans from this crisis when I was in Sierra Leone just before Christmas. They were of all ages, of course. Some of our work is to help UNICEF to provide the psycho-social support that they need and to keep the orphanages going. We are also helping to provide dedicated centres where children can be looked after safely if their parents go to community care centres to be tested because they are concerned that they have Ebola; if the parents end up being taken into care, they cannot look after their children.

There are huge child protection issues. I can reassure the hon. Lady that we are mindful of them, and mindful of the need to work not just with the Government of Sierra Leone but with civil society and the NGO sector to make sure that they are properly addressed.

The hon. Lady asks about the extent of our commitment. The £427 million that I have talked about is essentially the money that we are spending on providing ongoing support, including what we have already done, which has now cost more than £200 million. Over the coming months, we need to keep supporting the beds and the safe burials and all the very practical work that we are doing—social mobilisation, talking to communities—and also put in place a budget, which is about half the increase, for the initial planning on early recovery. We are steadily shifting our strategy to ensure that we have the capacity on the ground still to cope and deal with Ebola and get to zero. That is the principal objective that we have to meet, while transitioning to look at how we can safely open schools and hospitals and deal with some of the issues that the hon. Lady talks about in relation to communities.

The helicopter support has been absolutely vital. The road network is part of the development progress, but there is no doubt that fantastic work has been done by the Merlin helicopters. I had a chance during my trips to Sierra Leone to get to know some of the pilots—I was there regularly enough—and they have been working round the clock. I want personally to say a massive thank you to them. They were incredibly impressive and have really put in the flying hours over the past six months. The civilian helicopter provision will ensure that we can continue to get around Sierra Leone rapidly and that the district-level response is working effectively, which is why we have kept it in place.

On the important point about ensuring that, frankly, we get the international community to step up to the plate, particularly as recovery takes place, we are indeed investing a lot of time and effort in lobbying. The Brussels conference, which happened a couple of weeks ago, was absolutely key in really making sure that we got international focus on the need to get to zero, avoiding complacency and starting to present the forward look at what those recovery plans will need. The $400 million part is really the initial absolute priority investment that is required to start the recovery process and kick it off. There will be a follow-up conference at the UN, which will be more focused on pledging. We have worked directly with the Government of Sierra Leone to talk to them about how we can ensure that their recovery plan is of good quality and essentially investable and prioritised, and we will continue to do all that work.

The hon. Lady also asks about the Ebola vaccine trials. In fact, we had some vaccines ready to go for phase 2 trials because the UK and DFID had already worked with the Medical Research Council and Glaxo Wellcome to help to support Ebola vaccines in the phase 1 trials. One of the learnings from my perspective is being clearer as an international community about what kinds of vaccine we want to have in stock at phase 1 stage, in order to be able to put them rapidly into phase 2, which is more expensive, if crisis hits. Also, streamlining the regulatory procedures is important, so that we can get the vaccines tested more rapidly when there is a real public health crisis element to them. Obviously, we all appreciate that the regulatory environment is there for a reason, which is to protect patients, but in this case, it was vital that we looked at how we could fast-track the Ebola vaccines. The trials have started in Liberia already. They are about to be started in Sierra Leone and Guinea.

On the number of patients, if anything we have a challenge, because fewer people are suffering from Ebola, but as the hon. Lady will understand, that is the patient population on whom we are testing the vaccines.

On WHO reform, I have had a chance now on a number of occasions to see Margaret Chan, both in London and, most recently, in Brussels. The UK has been a leading player, most recently in the special session on WHO reform, playing a constructive a role in helping us all to learn about how not only the WHO but the international community can better respond to such a public health crisis in the future.

[Jeremy Lefroy (Stafford) (Con)]

I join the Secretary of State and the shadow Secretary of State in paying tribute to all those who have tackled this terrible disease, some losing their lives in doing so—Sierra Leoneans, Liberians, Guineans and all others, including the British workers. I pay tribute, too, to the Secretary of State for the leadership that she has shown in this crisis. In a video conference which I chaired last month with the president of the World Bank and parliamentarians from affected countries, all stressed the need, which the shadow Secretary of State mentioned, to strengthen health systems. We also talked about the possibility of doing stress tests of those health systems, in the way that has been modelled for the banking sector, to ensure that they are robust enough. Parliamentarians all agreed on this vital point. Can my right hon. Friend assure me that the United Kingdom will continue to work with Sierra Leone and the Governments of the other affected countries over the coming months and years, and ensure that we do not leave them at this time of need?

[Justine Greening]

Yes, I can. The Ebola crisis has shown why the work that we do in development is so important. We saw that countries in parts of west Africa that had better developed health care systems were able to withstand this unprecedented Ebola outbreak. However, in the case of Sierra Leone and Liberia particularly, which had experienced terrible civil wars and comparatively recently come out of them, although their health systems had dramatically improved, they were still at a nascent stage and were unable to withstand such an unprecedented outbreak. I can assure my hon. Friend that the UK will play a leading role, particularly in our relationship with Sierra Leone, which is unique.

I join my hon. Friend in paying tribute to the bravery of the Sierra Leonean community, who were the ones on the front line, many of them volunteers, who ran towards the crisis and were part of the effort to tackle it, at the very time when most people would have wanted to run in the opposite direction. They were overwhelmingly the ones who helped get the crisis under control, but I am proud of the UK effort in supporting that.

Oral Answers to Questions

Jeremy Lefroy Excerpts

Wednesday 4th February 2015 Commons Chamber

[Justine Greening]

I agree it is important that we play our role in the refugee crisis and provide refuge to people affected by it, which is precisely what we are doing. On helping children where they are—the overwhelming majority of children affected are still in the region—we are working hand in hand with the Lebanese Government to ensure that there is the capacity for children to get education. There is more to be done, but we can be proud of the leading role played by the UK.

[Jeremy Lefroy (Stafford) (Con)]

On the visit to Jordan and Lebanon by the International Development Committee last year we saw the huge amount of work that those countries are doing to support children affected by the conflicts. What is the Department doing to ensure that the children of Jordan and Lebanon do not suffer because of the huge burdens placed on their public school systems?

[Justine Greening]

We are working directly with both those Governments to ensure that our programmes help not only Syrian refugee children but, particularly in Lebanon, a host of children who were in school but perhaps did not get the textbooks they needed. We have provided a much broader package, and it is important that host communities are helped to cope with the strains that the refugees are putting on them.